Literature DB >> 26516417

Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?

Shima Shahbaz1, Marcella Manicardi1, Giovanni Guaraldi1, Paolo Raggi1.   

Abstract

After the successful introduction of highly active antiretroviral agents the survival of patients infected with the human immunodeficiency virus (HIV) in developed countries has increased substantially. This has allowed the surfacing of several chronic diseases among which cardiovascular disease (CVD) is prominent. The pathogenesis of CVD in HIV is complex and involves a combination of traditional and HIV related factors. An accurate assessment of risk of CVD in these patients is still elusive and as a consequence the most appropriate preventive and therapeutic interventions remain controversial.

Entities:  

Keywords:  Antiretroviral therapy; Atherosclerosis; Cardiovascular death; Cardiovascular risk; Dyslipidemia; Human immunodeficiency virus infection; Hypertension; Smoking

Year:  2015        PMID： 26516417      PMCID： PMC4620074          DOI： 10.4330/wjc.v7.i10.633

Source DB:  PubMed          Journal:  World J Cardiol


  95 in total

1.  The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis.

Authors:  M J Davies; J L Gordon; A J Gearing; R Pigott; N Woolf; D Katz; A Kyriakopoulos
Journal:  J Pathol       Date:  1993-11       Impact factor: 7.996

2.  Soluble P-selectin and the risk of future cardiovascular events.

Authors:  P M Ridker; J E Buring; N Rifai
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

3.  Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux.

Authors:  Bela F Asztalos; Zahedi Mujawar; Matthew P Morrow; Angela Grant; Tatiana Pushkarsky; Christine Wanke; Richard Shannon; Matthias Geyer; Frank Kirchhoff; Dmitri Sviridov; Michael L Fitzgerald; Michael Bukrinsky; Keith G Mansfield
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

4.  Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.

Authors:  Heidi M Crane; Stephen E Van Rompaey; Mari M Kitahata
Journal:  AIDS       Date:  2006-04-24       Impact factor: 4.177

5.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

6.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.

Authors:  Nikolas Wada; Lisa P Jacobson; Mardge Cohen; Audrey French; John Phair; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2013-01-03       Impact factor: 4.897

7.  Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy.

Authors:  Katherine Krauskopf; Mark L Van Natta; Ronald P Danis; Sapna Gangaputra; Lori Ackatz; Adrienne Addessi; Alex D Federman; Andrea D Branch; Curtis L Meinert; Douglas A Jabs
Journal:  J Int Assoc Provid AIDS Care       Date:  2013 Sep-Oct

8.  HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells.

Authors:  Patrick Duffy; Xinwen Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  J Surg Res       Date:  2009-03-04       Impact factor: 2.192

9.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

10.  HIV infection and cardiovascular disease in women.

Authors:  Julie A Womack; Chung-Chou H Chang; Kaku A So-Armah; Charles Alcorn; Jason V Baker; Sheldon T Brown; Matthew Budoff; Adeel A Butt; Cynthia Gibert; Matthew Bidwell Goetz; John Gottdiener; Stephen Gottlieb; Amy C Justice; David Leaf; Kathleen McGinnis; David Rimland; Maria C Rodriguez-Barradas; Jason Sico; Melissa Skanderson; Hilary Tindle; Russell P Tracy; Alberta Warner; Matthew S Freiberg
Journal:  J Am Heart Assoc       Date:  2014-10-16       Impact factor: 5.501
View more
  18 in total

1.  Early vascular aging in the HIV infected: Is arterial stiffness assessment the ideal tool?

Authors:  Carla M T Fourie; Aletta E Schutte
Journal:  Virulence       Date:  2017-05-03       Impact factor: 5.882

2.  Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Authors:  Chiara Diazzi; Giulia Brigante; Giulia Ferrannini; Anna Ansaloni; Lucia Zirilli; Maria Cristina De Santis; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Endocrine       Date:  2016-10-11       Impact factor: 3.633

Review 3.  Heart aging measured with coronary artery calcium scoring and cardiovascular risk assessment algorithms in HIV infected patients.

Authors:  Paolo Raggi; Catherine Corwin
Journal:  Virulence       Date:  2016-07-13       Impact factor: 5.882

Review 4.  HIV-1-Associated Atherosclerosis: Unraveling the Missing Link.

Authors:  Alison Kearns; Jennifer Gordon; Tricia H Burdo; Xuebin Qin
Journal:  J Am Coll Cardiol       Date:  2017-06-27       Impact factor: 24.094

Review 5.  Prevention of stroke in people living with HIV.

Authors:  Ivy Nguyen; Anthony S Kim; Felicia C Chow
Journal:  Prog Cardiovasc Dis       Date:  2020-01-31       Impact factor: 8.194

6.  Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.

Authors:  Michelle L D'Antoni; Brooks I Mitchell; Sara McCurdy; Mary Margaret Byron; Debra Ogata-Arakaki; Dominic Chow; Nehal N Mehta; William A Boisvert; Eric Lefebvre; Cecilia M Shikuma; Lishomwa C Ndhlovu; Yvonne Baumer
Journal:  J Leukoc Biol       Date:  2018-08-08       Impact factor: 4.962

7.  Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy.

Authors:  Ana Rita Gomes; Pedro Souteiro; Carolina Germana Silva; Bernardo Sousa-Pinto; Francisco Almeida; António Sarmento; Davide Carvalho; Paula Freitas
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

8.  Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action.

Authors:  Sophie Bauer; Mwanza Wa Mwanza; Roma Chilengi; Charles B Holmes; Zude Zyambo; Hansjakob Furrer; Matthias Egger; Gilles Wandeler; Michael J Vinikoor
Journal:  Glob Health Action       Date:  2017       Impact factor: 2.640

Review 9.  Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection.

Authors:  Daniela Sofia Martins Pinto; Manuel Joaquim Lopes Vaz da Silva
Journal:  Curr Cardiol Rev       Date:  2018-03-14

10.  Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls.

Authors:  Mosepele Mosepele; Linda C Hemphill; Walter Moloi; Sikhulile Moyo; Isaac Nkele; Joseph Makhema; Kara Bennett; Virginia A Triant; Shahin Lockman
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.